Prevalence of Metabolic Syndrome in Obese Pediatric Population: Relation to Serum Leptin Concentrations by Durá-Travé, Teodoro et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Prevalence of Metabolic Syndrome in Obese Pediatric
Population: Relation to Serum Leptin Concentrations
Teodoro Durá-Travé, Fidel Gallinas-Victoriano,
Leyre Lloreda-Martín, Alberto Ríos-Muñoz,
Inés Niyubahwe and Ander Ernaga-Lorea
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/65098
Provisional chapter
Prevalence of Metabolic Syndrome in Obese Pediatric
Population: Relation to Serum Leptin Concentrations
Teodoro Durá-Travé, Fidel Gallinas-Victoriano,
Leyre Lloreda-Martín, Alberto Ríos-Muñoz,
Inés Niyubahwe and Ander Ernaga-Lorea
Additional information is available at the end of the chapter
Abstract
Childhood obesity represents the most relevant nutritional disorder in our environment.
This  study examines  the  prevalence  of  metabolic  syndrome in  an  obese  pediatric
population and its relation to serum leptin concentrations. A cross-sectional clinical and
metabolic study was accomplished in a group of 106 obese children (47 males and 59
females). Patients were classified into prepubertal group (Tanner stage I) and pubertal
group  (Tanner  stages  II–V).  Prevalence  of  insulin  resistance  [homeostasis  model
assessment (HOMA)], hypertriglyceridemia, low high-density lipoprotein (HDL) and
arterial  hypertension (HTA) was 38.7,  45.3,  28.3 and 33.8%, respectively.  Metabolic
syndrome prevalence (30.2%) was significantly higher in the pubertal group (38%) than
the prepubertal group (23.2%). There was a positive correlation between leptin and body
mass index (BMI) (r  = 0.529), leptin and HOMA indexes (r  = 0.562) and leptin and
triglycerides (r = 0.314). In addition, there was a positive correlation between HOMA
indexes and triglycerides (r = 0.596). Clinical and metabolic disorders associated with
obesity and related to the so-called metabolic syndrome are already present in pediatric
population. Leptin could play an important role in the etiopathogenesis of the metabolic
syndrome.
Keywords: childhood obesity, insulin resistance, leptin, metabolic syndrome, trigly-
cerides, blood pressure
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1. Introduction
Childhood obesity represents the most relevant nutritional disorder in our environment [1, 2].
It usually initiates at early stages in life, when child feeding depends—almost exclusively—on
feeding habits and preferences in a family setting; it is subsequently exacerbated (by the time
of school attendance and/or adolescence), probably in relation to the adoption of unhealthy
feeding habits and lifestyle [3, 4].
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WC, waist circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-
chol, high-density lipoprotein cholesterol; OGTT, oral glucose tolerance test.
Table 1. Criteria for the diagnosis of the pediatric metabolic syndrome (all definitions considered a child as having the
metabolic syndrome when three or more of the following characteristics were present).
Additional studies—except for uncommon situations such as endocrine, genetic or metabolic
pathologies, which justify excess body weight—are used for the diagnosis and/or early
detection of metabolic complications and, particularly, the metabolic syndrome. This syn-
drome is characterized by a cluster of symptoms associated with obesity, such as insulin
resistance, arterial hypertension (HTA) and dyslipidemia, and its interest lies in the high
Adiposity - Epidemiology and Treatment Modalities150
predictive value for cardiovascular disease and type 2 diabetes in adulthood, especially when
it is already present in school children and/or adolescents [5–11].
In the pediatric age, there are no clearly defined parameters for its diagnosis, being several
different criteria proposed [12–19] (Table 1) on the basis of an extrapolation from clinical guides
of adult populations: WHO [20], the National Cholesterol Education Program’s Adult Treat-
ment Panel III [21], the European Group for the Study of Insulin Resistance [22] and the
International Diabetes Federation (IDF) [23]; this would explain the disparity in published data
with respect to the applied criteria [12–16]. Even when the International Diabetes Federation
(IDF) refers to the inability for diagnosis in school age, epidemiological data allow suspecting
that metabolic syndrome or its components are already present at early stages [23–29].
Leptin is an adipocytokine that, in addition to multiple neuroendocrine functions, has a role
in the regulation of energy balance as well as in carbohydrate and lipid metabolism and arterial
pressure regulation. In this way, many authors have suggested that leptin might be involved
in the etiopathogenesis of metabolic syndrome [30–32].
The aim of this work is to determine the prevalence of metabolic syndrome and its relation to
serum leptin concentrations in a group of obese pediatric population.
2. Methods
2.1. Patients
A clinical assessment and metabolic study was accomplished in all patients diagnosed with
obesity who attended follow-up consultation within the year 2014. Clinical evaluation was
conducted in one of the three offices of the Pediatric Endocrinology Unit of the Navarra
Hospital Complex. Pubertal stage was determined in each patient according to Tanner’s
criteria, and patients were classified into two different groups: prepubertal group (Tanner stage
I) and pubertal group (Tanner stages II–V).
All those patients with personal history of endocrine disease, malformation syndromes or
iatrogenic obesity (drug treatments) were excluded.
The metabolic syndrome was defined by modified Cook’s criteria [12] as the manifestation of
at least three of the following features: low HDL-cholesterol (<40 mg/dl), hypertriglyceridemia
(TG > 110 mg/dl), obesity, arterial hypertension and insulin resistance.
2.2. Clinical assessment
The assessment of weight and height was accomplished in underwear and barefoot. Weight
was measured using an Año-Sayol scale, with a reading interval of 0–120 kg and precision 100
g, and height was measured using a Holtain wall stadiometer ranging 60–210 cm and precision
0.1 cm. Body mass index (BMI) was calculated according to the corresponding formula: weight
(kg)/height2 (m). Values of Z score for BMI were calculated using a nutrition application
(Aplicación Nutricional) program from the Spanish Society of Pediatric Gastroenterology,
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Hepatology and Nutrition (available at http://www.gastroinf.es/nutritional/). The inclusion
criterion was BMI (Z score) values exceeding +2.0 (97th percentile) by age and sex according
to the growing charts from Ferrández et al. (Centro Andrea Prader, Zaragoza 2002) [33].
Blood pressure (BP) was measured in the right arm with the patient in the supine position
using Visomat comfort 20/40 (Roche Diagnostics Inc.) digital blood pressure monitor, record-
ing the lowest of three measurements. Arterial hypertension (HTA) was considered when
systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) was equal to or higher
than 95th percentile by age, sex and height from the American reference charts (National high
blood pressure Program in Children and Adolescents) [34].
The institutionalized program for Child Care in the Community of Navarre (Comunidad Foral
de Navarra, Spain) includes periodic health examinations at ages 1, 2, 3, 4, 6, 8, 10 and 12 years.
The anthropometric measurements (weight and height) are recorded in the corresponding
clinical history. This record has allowed the registration of the age of onset for obesity and the
time of evolution at the moment of the examination.
2.3. Metabolic study
Plasma concentrations for glucose, insulin, triglycerides, total cholesterol (total-chol), high-
density lipoprotein cholesterol (HDL-chol), low-density lipoprotein cholesterol (LDL-chol)
and leptin were measured under basal fasting conditions using standardized methodologies.
In order to determine insulin resistance, the homeostasis model-assessment (HOMA) indexes
were calculated from fasting glucose and insulin concentrations (glucose levels in mmol ×
insulin in μUml/L/22.5). Insulin resistance was considered when HOMA value was equal to
or higher than 3.8 [35].
2.4. Statistical analysis
Results are displayed as percentages (%) and means (M) with corresponding standard
deviations (SDS). Statistical analysis (descriptive statistics, Student’s T, chi-square test and
Pearson’s correlation) was done using the Statistical Packages for the Social Sciences version
20.0 (Chicago, IL, USA). Statistical significance was assumed when p value was lower than 0.05.
Parents and/or legal guardians were informed and provided verbal consent for the participa-
tion in this study in all cases. The study was approved by the Ethics Committee for Human
Investigation at our institution.
3. Results
The sample of patients consisted of 106 patients (47 males and 59 females). The prepubertal
group included 56 patients (22 males and 34 females) and the pubertal group included 50
patients (25 males and 25 females).
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Clinical data Prepubertal group Pubertal group Total
Age of onset (years)
Males 3.50 ± 1.75 5.10 ± 3.22** 4.35 ± 2.73
Females 3.38 ± 1.36 7.89 ± 3.56** 5.29 ± 3.37
Total 3.43 ± 1.51* 6.50 ± 3.65* 4.88 ± 3.12
Age at examination (years)
Males 8.78 ± 1.01 12.42 ± 1.43** 10.72 ± 2.21
Females 8.55 ± 1.26 13.22 ± 1.15** 10.53 ± 2.62
Total 8.64 ± 1.17* 12.82 ± 1.35* 10.61 ± 2.44
Evolution (years)
Males 5.27 ± 1.49 7.95 ± 2.86 6.64 ± 2.64
Females 5.16 ± 1.85 6.65 ± 2.71 5.71 ± 2.23
Total 5.21 ± 1.71* 7.35 ± 2.84* 6.14 ± 2.49
BMI (Z score)
Males 4.05 ± 1.13 3.95 ± 1.31** 4.00 ± 1.21**
Females 3.55 ± 1.27 2.60 ± 0.50** 3.14 ± 1.11**
Total 3.74 ± 1.23* 3.27 ± 1.20* 3.52 ± 1.23
Systolic BP (mmHg)
Males 113.68 ± 11.55 120.09 ± 14.74 116.88 ± 13.48
Females 108.78 ± 16.94 121.17 ± 16.10 113.96 ± 17.56
Total 110.77 ± 15.05* 120.64 ± 15.29* 115.26 ± 15.87
Diastolic BP (mmHg)
Males 67.22 ± 11.45 70.81 ± 17.08 69.02 ± 14.49
Females 67.59 ± 11.85 70.04 ± 12.27 68.61 ± 11.98
Total 67.44 ± 11.58 70.42 ± 14.65 68.79 ± 13.08
*p < 0.05 among age groups.
**p < 0.05 between sexes.
Table 2. Average values (M ± SD) for the clinical features in both age groups according to sex.
Table 2 lists and compares the clinical features in both groups according to pubertal stage and
sex. Within the pubertal group, the average values for age of onset, age at examination, years
of evolution and systolic blood pressure were significantly higher (p < 0.05); within the
prepubertal group, BMI values (Z score) at examination were higher (p < 0.05). There were no
statistically significant differences among the average values of diastolic blood pressure
between the different groups. The average BMI values (Z score) in the pubertal group were
significantly higher (p < 0.05) in males. Finally, within the pubertal group, the average values
for age of onset (obesity) were significantly lower (p < 0.05) in males.
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Biochemical data Prepubertal group Pubertal group Total
Glycemia (mg/dl)
Males 93.40 ± 10.58 92.92 ± 10.18 93.14 ± 10.39
Females 89.12 ± 7.55 90.16 ± 8.87 89.56 ± 8.08
Total 90.83 ± 9.17 91.54 ± 9.55 91.17 ± 9.31
Insulin (uU/ml)
Males 17.48 ± 14.58 18.22 ± 10.49 17.86 ± 12.52
Females 13.58 ± 9.70 23.82 ± 15.58 17.57 ± 13.18
Total 15.14 ± 11.93* 20.89 ± 13.31* 17.70 ± 12.82
HOMA
Males 3.50 ± 2.09 4.01 ± 1.64** 3.77 ± 1.86**
Females 3.17 ± 1.41 3.08 ± 1.25** 3.13 ± 1.34**
Total 3.30 ± 1.70 3.54 ± 1.52 3.42 ± 1.61
Total-chol (mg/dl)
Males 165.04 ± 27.34 152.72 ± 21.77 158.48 ± 25.05
Females 160.84 ± 27.18 157.32 ± 22.62 159.32 ± 25.17
Total 162.52 ± 27.07 155.02 ± 22.10 158.95 ± 25.00
LDL-chol (mg/dl)
Males 93.50 ± 27.51 87.86 ± 21.26 90.62 ± 24.40
Females 94.06 ± 27.58 87.50 ± 20.64 91.25 ± 24.85
Total 93.83 ± 27.29 87.68 ± 20.72 90.97 ± 24.53
HDL-chol (mg/dl)
Males 51.90 ± 11.31 43.30 ± 8.57** 47.51 ± 10.80
Females 49.48 ± 12.37 50.08 ± 9.93** 49.73 ± 11.32
Total 48.73 ± 9.76 47.25 ± 9.01 48.75 ± 11.09
Triglycerides (mg/dl)
Males 115.95 ± 65.88 126.36 ± 45.59 121.48 ± 55.62
Females 98.08 ± 42.87 104.32 ± 42.08 100.72 ± 42.29
Total 105.10 ± 53.27 115.34 ± 44.83 109.93 ± 49.50
Leptin (ng/ml)
Males 30.14 ± 11.75 34.38 ± 17.01** 32.39 ± 14.78**
Females 29.11 ± 12.43 24.66 ± 8.72** 27.22 ± 11.15**
Total 29.51 ± 12.07 29.52 ± 14.25 29.51 ± 13.08
*p < 0.05 among age groups.
**p < 0.05 between sexes.
Table 3. Average values (M ± SD) for metabolic study in both age groups according to sex.
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Table 3 displays and compares the average values for the results of blood tests among the
different groups according to pubertal stage and sex. Within the pubertal group, average
values for insulin were significantly higher (p < 0.05) than the prepubertal group. The average
values for HDL-chol within the pubertal group were significantly higher (p < 0.05) in females,
and the average values for HOMA and leptin within the pubertal group were significantly
higher (p < 0.05) in males.
There was a significant positive correlation (p < 0.05) between leptin plasma levels and BMI
values (r = 0.529; Figure 1). In addition, there was a significant positive correlation between
leptin plasma levels and HOMA indexes (r = 0.562; Figure 2). There was also a significant
positive correlation (p < 0.05) between HOMA indexes and plasma concentrations of trigly-
cerides (r = 0.596; Figure 3) as well as with age at examination (r = 0.207). And there was also
a significant positive correlation (p < 0.05) between leptin plasma levels and plasma concen-
trations of triglycerides (r = 0.314; Figure 4).
Table 4 presents and compares the percentage values for the different clinical and metabolic
parameters used as constituents of the metabolic syndrome in both groups. The percentage of
patients who showed systolic blood pressure values higher than 95th percentile for the applied
reference was significantly higher in the pubertal group (p < 0.05). There were no statistically
significant differences among both groups regarding the percentage of patients who present
HOMA index values higher than 3.8, plasma triglycerides higher than 110 mg/dl, HDL-chol
values lower than 40 mg/dl and diastolic blood pressure values higher than 95th percentile for
the applied reference charts. Within the pubertal group, the metabolic syndrome prevalence
(38%) was significantly higher (p < 0.05) than the prepubertal group (23.2%).
Figure 1. Leptin plasma levels (ng/ml) in relation to BMI (Z score).
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Figure 2. Leptin plasma levels (ng/ml) in relation to insulin resistance (HOMA).
Figure 3. Triglycerides plasma concentrations (mg/dl) in relation to insulin resistance (HOMA).
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Figure 4. Triglycerides plasma concentrations (mg/dl) in relation to leptin plasma levels (ng/ml).






HOMA > 3.8 21 (37.5) 20 (40.0) 41 (38.7)
Triglycerides > 110 mg/dl 23 (41.1) 25 (50.0) 48 (45.3)
HDL-chol < 40 mg/dl 13 (23.6) 17 (36.2) 30 (28.3)
SBP > p95th* 14 (25.9) 21 (46.7) 35 (33.8)
DBP > p95th* 9 (16.7) 7 (15.6) 16 (15.1)
Metabolic syndrome* 13 (23.2) 19 (38) 32 (30.2)
*p < 0.05 among age groups.
Table 4. Prevalence of the different diagnostic criteria of metabolic syndrome in both groups.
4. Discussion
The prevalence of metabolic syndrome within the whole sample was 30.2%, being significantly
higher in the pubertal group (38%) than the prepubertal group (23.2%). The comparison of
these results with those described by the other authors reveals that the prevalence found is
similar to references from Cook (28.7%) [12], De Ferranti (31.2%) [13], Weiss (38.7%) [14], Cruz
(30%) [15] and Viner (30%) [16] in obese United Kingdom or American children and adoles-
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cents, although slightly higher than references from Lopez-Capapé (18%) [25], Tapia (18.6%)
[27] and Olza (16.8%) [28] in Spanish obese pediatric population. Nevertheless, the contrast of
the rate of prevalence from different studies has a relative value, since the criteria applied are
different, and even different cut points for each component of metabolic syndrome are used
[26, 28].
This study follows Cook modified criteria (abdominal perimeter has been replaced by BMI in
the assessment of obesity, and fasting plasma glucose higher than 110 mg/dl has been replaced
by HOMA index higher than 3.8). These criteria have gradually acquired clinical relevance in
the assessment of metabolic syndrome in pediatric age and support from the scientific
community [12, 25, 27, 28, 31]; this allows, on one side, the achievement of comparisons among
the results of the different national and international studies and, on the other side, justifies its
use as reference diagnosis criteria in this work.
The IDF considers fat distribution and, concretely, central or visceral obesity—which is defined
by abdominal perimeter—as a “sine qua non” criterion for the diagnosis of metabolic syn-
drome due to its high predictive value for cardiovascular disease in adult life [36, 37]. However,
there is some controversy regarding the adequacy of its use as a main and/or necessary
diagnostic criterion [38]; in fact, recent studies conducted in pediatric population have used
both abdominal perimeter [12, 13, 15, 39] and BMI [14, 16, 18, 25] interchangeably. In this case,
the inclusion criterion was BMI value (Z-score) higher than +2.0 (97th percentile) by age and
sex according to the growing charts from Ferrández et al. (Centro Andrea Prader, Zaragoza
2002) [33].
Insulin resistance, as several authors have highlighted [16, 25], has been a very frequently noted
metabolic disorder in the population studied. It is worth indicating that, when Reaven [40]
described the syndrome X, he considered insulin resistance as the determining pathophysio-
logical factor and, in fact, the WHO included it as main and necessary criterion in order to
diagnose the metabolic syndrome [20]. However, the diagnosed criteria subsequently pro-
posed by the National Cholesterol Education Programs Adult Treatment Program III [21] and
the IDF [23] opted for a “lipid centric” theory, with special focus on dyslipidemia and/or fat
distribution.
Even though several criteria have been used to evaluate peripheral insulin sensitivity and/or
alterations in glucose metabolism (fasting glucose, glycemia after an oral glucose tolerance test
(OGTT), fasting insulin levels, etc.), the use of a mathematical model called homeostasis model
assessment (HOMA) as a criterion for insulin resistance has been widely contrasted as an early
disorder in glucose homeostasis (hyperinsulinemia with euglycemia). In this case, despite the
application of a quite restrictive cut point [21], insulin resistance was already detected in 39%
of the patients included in the study. In addition, the existing correlation between the HOMA
indexes and the age of the patients at the moment of examination suggests that the onset of
this metabolic comorbidity associated with obesity is related to hormonal changes concomitant
with puberty rather than to the evolution time of obesity.
The situation of insulin resistance usually involves a disturbance in lipid profile by stimulating
lipolysis and, therefore, an increase in plasma exchange of fatty acids that, at the same time,
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stimulate the hepatic triglyceride synthesis. This explains its correlation with the HOMA index
of the patients. In addition, the concentration of low-density lipoproteins is usually in normal
range while the concentration of high-density lipoproteins is usually low, being this considered
as a side effect of hypertriglyceridemia [41–43]. Dyslipidemia observed in patients with insulin
resistance corresponded with the situation expected in this metabolic condition. Furthermore,
hyperinsulinemia causes water and sodium retention and activates the sympathetic nervous
system, contributing to the development of hypertension.
Leptin participates directly in the regulation of energy homeostasis through an anorectic effect
and an increase in thermogenesis. Plasma concentrations reflect the reserve of organic fat and
are considered as a predictive factor for insulin resistance [44]. This would explain, on one
hand, the existing correlation between plasma concentrations and BMI, and, on the other hand,
the correlation with the HOMA index in the patients included in this work. In addition, leptin
stimulates lipolysis in adipocytes and, consequently, contributes to dyslipidemia (there was a
correlation with leptin plasma levels and triglycerides); it also stimulates angiogenesis and/or
endothelial dysfunction and would explain, to a great extent, the development of hypertension,
which is frequently associated with obesity [30]. Instead, it has been reported that adiponectin
has a paradoxical effect. Adiponectin levels correlate negatively with insulin and triglyceride
concentrations and BMI and positively with insulin sensitivity and high-density lipoprotein
levels. Adiponectin increases fatty acid combustion and decreases triglyceride content in the
liver and skeletal muscle and thus increases insulin sensitivity [45, 46]. Recently, several
authors had suggested that leptin/adiponectin ratio could be a better biomark for metabolic
syndrome [47–49].
As a conclusion, we remark the finding of clinical and metabolic disorders associated with
obesity and related to the so-called metabolic syndrome, which, to a great extent, are already
present in pediatric population. In the same way, the positive correlation between leptin
plasma levels and BMI values, HOMA indexes and plasma concentrations of triglycerides
suggests that leptin could play an important role in the etiopathogenesis of metabolic syn-
drome and/or comorbidities that are associated with obesity.
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